Drug Profile
Pentoxifylline - sanofi-aventis
Alternative Names: BL 191; Claudicat; Dospan Pento; Elorgan; Oxpentifylline; Pentoxifilina; TrentalLatest Information Update: 16 Dec 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Anti-inflammatories; Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
- Mechanism of Action Cytokine inhibitors; Immunosuppressants; Phosphoric diester hydrolase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Intermittent claudication; Tinnitus
- Discontinued HIV-1 infections; Kaposi's sarcoma; Lung disorders; Transplant rejection
Most Recent Events
- 27 Aug 2004 No development reported - Clinical-Phase-Unknown for Kaposi's sarcoma in USA (PO)
- 27 Aug 2004 No development reported - Preclinical for HIV-1 infections in Spain (unspecified route)
- 27 Aug 2004 No development reported - Preclinical for Lung disorders in Germany (unspecified route)